Testing TUDCA for high blood pressure in adults
Tests TUDCA against a placebo in adults with hypertension, high blood pressure.
Key facts
- Who runs it
- University of North Texas Health Science Center
- Where
- Fort Worth, United StatesSee the site
- Trial code
- Registry title
- Targeting Endoplasmic Reticulum Stress in Human Hypertension
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 70 people, planned
- Started
- 15 Aug 2023
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- TUDCA
- Placebo
- Record updated
- 28 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 who do not use tobacco or nicotine, with normal screening exam and ECG results. It tests a drug against a placebo.
- Age
- 18 to 80 years
- Sex
- Women and men can join.
- Disease stage
- Blood pressure at screening must be below 140 mmHg (systolic) and below 90 mmHg (diastolic). Resting systolic blood pressure of 100 mmHg or lower is also not allowed.
- Earlier treatment
- No tobacco or nicotine use in the last 6 months. No beta blockers, anti-coagulant therapy or hormone replacement therapy. No blood donation in the last 60 days.
- Biomarker or test result
- HbA1c must not be above 5.6. Pregnancy test must be negative for women who can become pregnant. ECG must be normal.
Main reasons for not taking part
- Body mass index above 35, unless athletic or muscular build
- Pregnancy or breastfeeding
- Implanted medical device such as a pacemaker
- Past stroke, heart attack, heart failure or other heart events
- Current cancer, anemia, asthma or lung disease
The registry criteria, word for word
Show all 33 criteriaShow less
Who can take part
- 18 to 80 years of age
- No tobacco/nicotine use within preceding 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches)
- Systolic blood pressure <140 mmHg; diastolic blood pressure <90 mmHg (obtained at the Screening and Familiarization Visit)
- Normal 12-lead ECG (obtained at the Screening and Familiarization Visit and reviewed by a board-certified physician)
- Normal clinical results from a medical exam reviewed by a board-certified physician (e.g., General Health Questionnaire obtained at the Screening and Familiarization Visit)
- Body mass index (BMI) <35 unless athletic/muscular build; calculation = body weight (kg)/height (m2)
- Females only: documentation of a negative pregnancy test prior to the familiarization and experimental sessions unless post-menopausal
Who cannot take part
- Women who are prescribed a continually releasing hormonal contraceptive (e.g. NuvaRingTM or other hormone releasing vaginal rings, Depo Provera shot, or birth control implants such as Nexplanon)
- Use of prescription drugs, non-prescription drugs, dietary supplements or herbal medicines known to alter vascular function unless cleared prior to the study
- Use of anti-coagulant therapy
- Current use of hormone replacement therapy (e.g., estrogen, testosterone)
- History of cerebrovascular abnormalities (e.g., prior stroke, transient ischemic attacks, epilepsy)
- Any prior history of anaphylaxis, not just prior reactions to the materials used in this study
- Implanted medical devices (e.g. cardiac pacemaker)
- Current or past history of hyperthyroidism, or other thyroid hormone-related disease
- Abnormal 12-lead ECG or uncontrolled heart rhythm issues causing symptoms, or an unstable blood pressure
- Known history of atherosclerosis of the carotid arteries (i.e., plaque formation)
- History of concussion and or other loss of consciousness within the preceding 30 days
- Autonomic dysfunction (e.g., Shy-Drager Syndrome, Bradbury-Eggleston syndrome, sinus arrhythmia, idiopathic orthostatic hypotension, fainting disorder)
- Respiratory illnesses (e.g., chronic asthma (including exercise-induced asthma), Chronic Obstructive Pulmonary Disease, Reactive Airway Disease)
- HbA1c >5.6
- Latex allergy aa) Known allergies or sensitivities to substances used in the study (e.g., Lidocaine HCL, sodium nitroprusside, acetylcholine, phentolamine, L-NAME, TUDCA, or related drugs) bb) Donated blood within the last 60 days cc) History or family history of abnormal blood clotting, clots in deep veins in the legs or pelvis, or blood clots to the lungs dd) History of alcohol or drug abuse which inhibits the subject's ability to complete this study ee) Individuals who have had mastectomies ff) History of methemoglobinemia gg) Current diagnosis of anemia hh) Current Fever (oral temp >99.5 °F/ 37.5 °C) ii) Current use of PDE3 inhibitors (e.g., Viagra) or soluble guanylate cyclase (sGC) stimulators (e.g., riociguat), or unwillingness to withhold medication for 2 weeks prior to laboratory testing jj) Current diagnosis of cancer kk) Cardiac surgery or cardiac events (e.g., coronary artery bypass graft surgery, myocardial infarction, heart failure) ll) Diagnosis of neurological disease or cognitive dysfunction
- Not meeting the defined age criteria
- Body mass index (BMI) >35 unless athletic/muscular build; calculation = body weight (kg)/height (m2)
- Any tobacco/nicotine use within the last 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches)
- Positive pregnancy test
- Females with an erratic/irregular menstrual cycle
- Females who are breastfeeding
- Subjects who weigh less than 80 lbs
- Use of beta blockers
- Daily use of bronchodilators
- Resting systolic blood pressure of <100 mmHg; >140mmHg or diastolic blood pressure >90mmHg
- Severe phobia of needles
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
- University of North Texas Health Science CenterFort Worth, United StatesContact: Steven A Romero, PhDTaking people
About the trial
What the trial wants to find out
There is strong evidence suggesting that endoplasmic reticulum stress contributes to neurogenic and vascular hypertension in various animal models, however this has never been explored in humans. Therefore, this project will fill this gap by performing a single-blind, placebo-controlled trial in humans with hypertension.
The 2 groups in the trial
- Endoplasmic Reticulum Stress InhibitionTreatment being tested
Treatment: TUDCA
- PlaceboPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Targeting Endoplasmic Reticulum Stress in Human Hypertension
- Plain-language title
- Testing TUDCA for high blood pressure in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06025630, who can take part
- Record updated
- 28 March 2025